US 10,376,513 B2
Heterocyclylamines as PI3K inhibitors
Richard B. Sparks, Wilmington, DE (US); Andrew P. Combs, Kennett Square, PA (US); Brent Douty, Fallowfield, PA (US); Yun-Long Li, Chadds Ford, PA (US); Song Mei, Wilmington, DE (US); and Eddy W. Yue, Landenberg, PA (US)
Assigned to Incyte Holdings Corporation, Wilmington, DE (US); and Incyte Corporation, Wilmington, DE (US)
Filed by Incyte Corporation, Wilmington, DE (US); and Incyte Holdings Corporation, Wilmington, DE (US)
Filed on Aug. 24, 2018, as Appl. No. 16/112,160.
Application 16/112,160 is a continuation of application No. 15/673,529, filed on Aug. 10, 2017, granted, now 10,092,570.
Application 15/673,529 is a continuation of application No. 14/872,881, filed on Oct. 1, 2015, granted, now 9,730,939.
Application 14/872,881 is a continuation of application No. 13/601,349, filed on Aug. 31, 2012, granted, now 9,199,982.
Claims priority of provisional application 61/677,445, filed on Jul. 30, 2012.
Claims priority of provisional application 61/594,882, filed on Feb. 3, 2012.
Claims priority of provisional application 61/530,866, filed on Sep. 2, 2011.
Prior Publication US 2019/0134040 A1, May 9, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/519 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 519/00 (2006.01)
CPC A61K 31/519 (2013.01) [C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 519/00 (2013.01)] 21 Claims
 
1. A method of inhibiting an activity of a phosphoinositide 3-kinase delta (PI3Kδ), comprising contacting the kinase with a compound, which is 5-{3-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}-1,3-oxazolidin-2-one, or a pharmaceutically acceptable salt thereof.